Earnings report 📈 Stocks 🌍 Denmark

ChemoMetec Q1 Revenue Climbs 28% to DKK 160M on Strong Instrument Sales

ChemoMetec posted a 28% revenue increase and 46% EBITDA growth in Q1 2026/27, fueled by a 61% surge in instrument sales and the successful market penetration of its new NC-203 platform.

📅 November 5, 2026 🕐 1 min read

1 assets impacted. Net bias: 1 Bullish, 0 Bearish, 0 Neutral. Strongest signal: CHEMM.CO ↑ 7/10 (88% confidence).

📊 Affected Assets (1)

CHEMM.CO

Bullish 🤖 88%

📅 Short-term 🌍 DK · Explicit

ChemoMetec's Q1 2026/27 revenue rose 28% to DKK 160.0 million and EBITDA rose 46% to DKK 100.3 million, with a 63% margin. Instrument sales rose 61%, NC-203 sales exceeded DKK 20 million versus DKK 0 a year earlier and quadrupled from Q4 2025/26, and the positive trend continued into early Q2. Geopolitical and macroeconomic uncertainty are cited risks.

Catalysts

▲ Q1 2026/27 revenue increased 28% to DKK 160.0 million from DKK 124.6 million
▲ EBITDA increased 46% to DKK 100.3 million, taking the EBITDA margin to 63%

Risk Factors

▼ Geopolitical escalation, rising energy prices and uncertainty about trade policy, interest rates and exchange rates may affect customers' investment priorities
▼ Potential consequences of the US midterm election outcome are cited as a separate risk factor

▼ Show FAQ (2) ▲ Hide FAQ

How fast did ChemoMetec's revenue and earnings grow in Q1 2026/27?

Revenue rose 28% to DKK 160.0 million from DKK 124.6 million, and EBITDA rose 46% to DKK 100.3 million from DKK 68.8 million.

What drove the growth in instrument sales?

Instrument sales rose 61% to DKK 65.6 million, driven by the XcytoMatic range, especially NC-203 sales exceeding DKK 20 million versus DKK 0 a year earlier.

🎯 Key Takeaways

Q1 revenue reached DKK 160.0 million, a 28% increase, while EBITDA rose 46% to DKK 100.3 million.
Instrument sales jumped 61% to DKK 65.6 million, led by the NC-203 which exceeded DKK 20 million in sales.
Management maintains a positive outlook, citing strong demand trends continuing into early Q2 despite geopolitical and macroeconomic risks.

📝 Executive Summary

ChemoMetec reported a strong start to fiscal 2026/27, with Q1 revenue rising 28% to DKK 160.0 million. EBITDA surged 46% to DKK 100.3 million, supported by a 63% margin, driven by robust demand for the new NC-203 instrument and strict cost controls. The company noted that instrument sales grew 61% year-over-year, with the NC-203 platform significantly outperforming expectations.

❓ FAQ

How fast did ChemoMetec's revenue and earnings grow in Q1 2026/27?

Revenue rose 28% to DKK 160.0 million from DKK 124.6 million, and EBITDA rose 46% to DKK 100.3 million from DKK 68.8 million.

What drove the growth in instrument sales?

Instrument sales rose 61% to DKK 65.6 million, driven by the XcytoMatic range, especially NC-203 sales exceeding DKK 20 million versus DKK 0 a year earlier.

📰 Related Articles

🏷️ Tags

📰 Source

🔗 View Original Article